Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pharnext

News headline image
Pharnext Appoints Antoine Gravelle as General Counsel
From Pharnext
Via AccessWire
Topics Intellectual Property
News headline image
Pharnext: Findings on Symptoms Burden of Charcot-Marie-Tooth Disease Type 1A From the ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the ICNMD 2022
From Pharnext
Via AccessWire
News headline image
Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors
From Pharnext
Via AccessWire
News headline image
Pharnext Announces Successful Debt Refinancing and New Loan Agreement
From Pharnext
Via AccessWire
Topics Bonds
News headline image
Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase III Trial of PXT3003, the PREMIER Trial, for the Treatment of Charcot-Marie-Tooth Disease Type 1A
From Pharnext
Via AccessWire
News headline image
Pharnext: The Latest Findings From CMT&Me, a ‘Real-World’ Digital Lifestyle Study on Charcot-Marie-Tooth Diseases (‘CMTs’), to be Presented at the 2022 Peripheral Nerve Society (‘PNS’) Annual Meeting
From Pharnext
Via AccessWire
News headline image
Joshua Schafer Appointed as Interim Chairman of Pharnext Board of Directors
From Pharnext
Via AccessWire
Topics Artificial Intelligence
News headline image
Pharnext Appoints Valérie Worrall as Chief Financial Officer
From Pharnext
Via AccessWire
Topics Artificial Intelligence
News headline image
Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
From Pharnext
Via AccessWire
Topics Artificial Intelligence
News headline image
Pharnext and Global Tech Opportunities 13 Agree to Stop Convertible Bond Program from End of May 2022
From Pharnext
Via AccessWire
Topics Artificial Intelligence Bonds
News headline image
Pharnext Appoints Dr. Burkhard Blank as New Chief Medical Officer and Head of Research & Development
From Pharnext
Via AccessWire
Topics Artificial Intelligence
News headline image
Pharnext Confirms Details for 2021 Hybrid Research & Development Day
From Pharnext
Via AccessWire
Topics Artificial Intelligence
News headline image
Pharnext Strengthens its Management Team with Three Key Appointments to Support Ongoing Development of PXT3003 Toward Approval and Commercialization
From Pharnext
Via AccessWire
Topics Artificial Intelligence
News headline image
Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT Trial, Published in the Orphanet Journal of Rare Diseases
From Pharnext
Via AccessWire
Topics Artificial Intelligence
News headline image
Pharnext Reports First Half 2021 Financial Results
From Pharnext
Via AccessWire
Topics Artificial Intelligence Bonds
News headline image
Pharnext to Host 2021 Hybrid Research & Development Day
From Pharnext
Via AccessWire
Topics Artificial Intelligence
News headline image
Piers Morgan Joins Pharnext's Board of Directors
From Pharnext
Via AccessWire
Topics Artificial Intelligence
News headline image
Pharnext Announces First Patient Enrolled in Europe in the PREMIER Trial, its Pivotal Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A ('CMT1A')
From Pharnext
Via AccessWire
Topics Artificial Intelligence
News headline image
Pharnext: Shareholder Letter
From Pharnext
Via AccessWire
Topics Artificial Intelligence Bonds
News headline image
Pharnext Announces a New Financing Through a Convertible Bond Program for a Total Amount up to €81 Million Gross to Extend its Cash Runway and to Continue to Fund its Pivotal Phase III Study
From Pharnext
Via AccessWire
Topics Artificial Intelligence Bonds
News headline image
Pharnext Reports Financial Results for Year-End 2020
From Pharnext
Via AccessWire
Topics Artificial Intelligence Bonds
Tickers PNEXF
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.